Keywords
Intradermal skin test
In vitro diagnosis of allergy
Molecular allergy diagnosis
Immunotherapy with allergens
Subcutaneous immunotherapy
Sublingual immunotherapy
Immunotherapy with hymenoptera venom
Anaphylaxis
Adrenaline
Abstract
Background: In Mexico, allergen immunotherapy (AIT) and immunotherapy with hymenoptera venom (VIT) is traditionally practiced combining aspects of the European and American school. In addition, both types of extracts (European and American) are commercially available in Mexico. Moreover, for an adequate AIT/VIT a timely diagnosis is crucial. Therefore, there is a need for a widely accepted, up-to-date national immunotherapy guideline that covers diagnostic issues, indications, dosage, mechanisms, adverse effects and future expectations of AIT (GUIMIT 2019).
Method: With nationwide groups of allergists participating, including delegates from postgraduate training-programs in Allergy/Immunology-forming, the guideline document was developed according to the ADAPTE methodology: the immunotherapy guidelines from European Academy of Allergy and Clinical Immunology, German Society for Allergology and Clinical Immunology, The American Academy of Allergy, Asthma and Immunology and American College of Allergy, Asthma, and Immunology were selected as mother guidelines, as they received the highest AGREE-II score among international guidelines available; their evidence conforms the scientific basis for this document.
Results: GUIMIT emanates strong or weak (suggestions) recommendations about practical issues directly related to in vivo or in vitro diagnosis of IgE mediated allergic diseases and the preparation and application of AIT/VIT and its adverse effects. GUIMIT finishes with a perspective on AIT modalities for the future. All the statements were discussed and voted on until > 80 % consensus was reached.
Conclusion: A wide and diverse group of AIT/VIT experts issued transculturized, evidence-based recommendations and reached consensus that might improve and standardize AIT practice in Mexico.
References
Larenas-Linnemann D, Ortega-Martell JA, Del Río-Navarro B, Rodríguez-Pérez N, Arias-Cruz A, Estrada A, et al. Guía Mexicana de Práctica Clínica de Inmunoterapia 2011. Rev Alerg Mex. 2011;58(1):3-75.
Esposito S, Isidori C, Pacitto A, Salvatori C, Sensi L, Frati F, et al. Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: a review of the literature. J Transl Med. 2018;16(1):329. DOI: 10.1186/s12967-018-1701-6
Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, et al. Intralymphatic immunotherapy: update and unmet needs. Int Arch Allergy Immunol. 2019;178(2):141-149. DOI: 10.1159/000493647
Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;63(12):1308-1311. DOI: 10.1503/cmaj.090449
Larenas-Linnemann DES, Antolin-Amerigo D, Parisi C, Nakonechna A, Luna-Pech JA, Wedi B, et al. National clinical practice guidelines for allergen immunotherapy: an international assessment applying AGREE-II. Allergy. 2018;73(3):664-672. DOI: 10.1111/all.13316
Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI Guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798. DOI: 10.1111/all.13317
Halken S, Larenas-Linnemann D, Roberts G, Calderon MA, Angier E, Pfaar O, et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017;28(8):728-745. DOI: 10.1111/pai.12807
Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282-319. DOI: 10.1007/s40629-014-0032-2
Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(Suppl 1):S1-S55. Disponible en: https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Allergen-immunotherapy-Jan-2011.pdf
Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test-European standards. Clin Transl Allergy. 2013;3(1):3. DOI: 10.1186/2045-7022-3-3
Rueff F, Bergmann KC, Brockow K, Fuchs T, Grubl A, Jung K, et al. [Skin tests for diagnostics of allergic immediate-type reactions. Guideline of the German Society for Allergology and Clinical Immunology]. Pneumologie. 2011;65(8):484-495. DOI: 10.1055/s-0030-1256476
Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(Suppl 3):S1-S148.
Larenas-Linnemann D, Luna-Pech JA, Mosges R. Debates in allergy medicine: allergy skin testing cannot be replaced by molecular diagnosis in the near future. World Allergy Organ J. 2017;10(1):32. DOI: 10.1186/s40413-017-0164-1
Larenas-Linnemann DE, Fogelbach GA, Alatorre AM, Cruz AA, Colin DD, Pech JA, et al. Patterns of skin prick test positivity in allergic patients: usefulness of a nationwide SPT chart review. Allergol Immunopathol (Madr). 2011;39(6):330-336. DOI: 10.1016/j.aller.2010.09.006
Larenas-Linnemann D, Michels A, Dinger H, Shah-Hosseini K, Mosges R, Arias-Cruz A, et al. Allergen sensitization linked to climate and age, not to intermittent-persistent rhinitis in a cross-sectional cohort study in the (sub)tropics. Clin Transl Allergy. 2014;4:20. DOI: 10.1186/2045-7022-4-20
Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62(3):317-324. DOI: 10.1111/j.1398-9995.2006.01312.x
Nassiri M, Babina M, Dolle S, Edenharter G, Rueff F, Worm M. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol. 2015;135(2):491-499. DOI: 10.1016/j.jaci.2014.09.004
Larenas-Linnemann D, Esch RE, Guidos-Fogelbach G, Rodríguez-Pérez N. A comparison of in vitro potency between European and Mexican allergen extracts and US (CBER/FDA) reference extracts. Allergol Immunopathol (Madr). 2010;38(4):170-173. DOI: 10.1016/j.aller.2009.11.005
Oppenheimer J, Nelson HS. Skin testing: a survey of allergists. Ann Allergy Asthma Immunol. 2006;96(2 Suppl 1):S6-S12.
Nugent JS, Quinn JM, McGrath CM, Hrncir DE, Boleman WT, Freeman TM. Determination of the incidence of sensitization after penicillin skin testing. Ann Allergy Asthma Immunol. 2003;90(4):398-403. DOI: 10.1016/S1081-1206(10)61823-6
Jensen-Jarolim E, Jensen AN, Canonica GW. Debates in allergy medicine: molecular allergy diagnosis with ISAC will replace screenings by skin prick test in the future. World Allergy Organ J. 2017;10(1):33. DOI: 10.1186/s40413-017-0162-3
Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, et al. EAACI molecular allergology user’s guide. Pediatr Allergy Immunol. 2016;27(Suppl 23):1-250. DOI: 10.1111/pai.12563
Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011;31(1):61-75. DOI: 10.1016/j.nutres.2011.01.001
Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE, et al. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013;6(1):17. DOI: 10.1186/1939-4551-6-17
Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70(11):1393-1405. DOI: 10.1111/all.12698
Wang J, Godbold JH, Sampson HA. Correlation of serum allergy (IgE) tests performed by different assay systems. J Allergy Clin Immunol. 2008;121(5):1219-1224. DOI: 10.1016/j.jaci.2007.12.1150
Hamilton RG, Williams PB; Specific IgE Testing Task Force of the American Academy of Allergy A, Immunology, American College of Allergy, Asthma, and Immunology. Human IgE antibody serology: a primer for the practicing North American allergist/immunologist. J Allergy Clin Immunol. 2010;126(1):33-38. DOI: 10.1016/j.jaci.2010.03.014
Heffner KL, Kiecolt-Glaser JK, Glaser R, Malarkey WB, Marshall GD. Stress and anxiety effects on positive skin test responses in young adults with allergic rhinitis. Ann Allergy Asthma Immunol. 2014;113(1):13-18. DOI: 10.1016/j.anai.2014.03.008
Brandström J, Nopp A, Johansson SG, Lilja G, Sundqvist AC, Borres MP, et al. Basophil allergen threshold sensitivity and component-resolved diagnostics improve hazelnut allergy diagnosis. Clin Exp Allergy. 2015;45(9):1412-1418. DOI: 10.1111/cea.12515
Moreno C, Justicia JL, Quiralte J, Moreno-Ancillo A, Iglesias-Cadarso A, Torrecillas M, et al. Olive, grass or both? Molecular diagnosis for the allergen immunotherapy selection in polysensitized pollinic patients. Allergy. 2014;69(10):1357-1363. DOI: 10.1111/all.12474
Sastre J, Landivar ME, Ruiz-Garcia M, Andregnette-Rosigno MV, Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy. 2012;67(5):709-711. DOI: 10.1111/j.1398-9995.2012.02808.x
Bousquet J, Anto JM, Akdis M, Auffray C, Keil T, et al. Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015. Allergy. 2016;71(11):1513-1525. DOI: 10.1111/all.12880
Letrán A, Espinazo M, Moreno F. Measurement of IgE to pollen allergen components is helpful in selecting patients for immunotherapy. Ann Allergy Asthma Immunol. 2013;111(4):295-297. DOI: 10.1016/j.anai.2013.07.005
Werfel T, Asero R, Ballmer-Weber BK, Beyer K, Enrique E, Knulst AC, et al. Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens. Allergy. 2015;70(9):1079-1090. DOI: 10.1111/all.12666
Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315(16):1715-1725. DOI: 10.1001/jama.2016.3964
Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017;140(6):1485-1498. DOI: 10.1016/j.jaci.2017.10.010
Sampson HA, O’Mahony L, Burks AW, Plaut M, Lack G, Akdis CA. Mechanisms of food allergy. J Allergy Clin Immunol. 2018;141(1):11-19. DOI: 10.1016/j.jaci.2017.11.005
Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288-1296. DOI: 10.1016/j.jaci.2013.01.049
Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-562.
Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6. DOI: 10.1186/1939-4551-7-6
Palomares O, Akdis M, Martin-Fontecha M, Akdis CA. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol Rev. 2017;278(1):219-236. DOI: 10.1111/imr.12555
Varricchi G, Harker J, Borriello F, Marone G, Durham SR, Shamji MH. T follicular helper (Tfh) cells in normal immune responses and in allergic disorders. Allergy. 2016;71(8):1086-1094. DOI: 10.1111/all.12878
Sage PT, Sharpe AH. T follicular regulatory cells. Immunol Rev. 2016;271(1):246-259. DOI: 10.1111/imr.12411
Shamji MH, Kappen JH, Akdis M, Jensen-Jarolim E, Knol EF, Kleine-Tebbe J, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper. Allergy. 2017;72(8):1156-1173. DOI: 10.1111/all.13138
Weber RW. Guidelines for using pollen cross-reactivity in formulating allergen immunotherapy. J Allergy Clin Immunol. 2008;122(1):219-221. DOI: 10.1016/j.jaci.2008.05.034.
Esch RE. Allergen immunotherapy: what can and cannot be mixed? J Allergy Clin Immunol. 2008;122(3):659-660. DOI: 10.1016/j.jaci.2008.07.018
Rodríguez-Pérez N, Ambriz-Moreno MJ, Pizarro-Esquivel U. Reacciones sistémicas no fatales por inmunoterapia y pruebas cutáneas. Rev Alerg Mex. 2002;49(3):69-73.
González-Díaz SN, De la Rosa-López JH, Arias-Cruz A, Macías-Weinmann A, Herrera-Castro D, Rodríguez-Ortiz P, et al. Reacciones sistémicas relacionadas a la inmunoterapia con alergenos en Monterrey, México. Rev Alerg Mex. 2011;58(2):79-86.
Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008-2013). Ann Allergy Asthma Immunol. 2016;116(4):354-359. DOI: 10.1016/j.anai.2016.02.001
Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113(6):1129-1136. DOI: 10.1016/j.jaci.2004.02.006
Casanovas M, Martin R, Jiménez C, Caballero R, Fernández-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol. 2006;139(2):153-158. DOI: 10.1159/000090392
Schaffer FM, Naples AR, Ebeling M, Hulsey TC, Garner LM. The safety of self-administered allergen immunotherapy during the buildup and maintenance phases. Int Forum Allergy Rhinol. 2015;5(2):149-156. DOI: 10.1002/alr.21443
Consejo de Salubridad General. Modelo de seguridad del paciente. México: Consejo de Salubridad General; 2015.
Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf. 2000;23(4):323-332. DOI: 10.2165/00002018-200023040-00005
Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006;117(1):169-175. DOI: 10.1016/j.jaci.2005.10.010
De Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009;64(6):963-964. DOI: 10.1111/j.1398-9995.2009.01998.x
Cochard MM, Eigenmann PA. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol. 2009;124(2):378-379. DOI: 10.1016/j.jaci.2009.04.040
Nichani JR, De Carpentier J. Safety of sublingual grass pollen immunotherapy after anaphylaxis. J Laryngol Otol. 2009;123(6):683-684. DOI: 10.1017/S0022215108002879
Greenhawt M, Oppenheimer J, Nelson M, Nelson H, Lockey R, Lieberman P, et al. Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update. Ann Allergy Asthma Immunol. 2017;118(3):276-282. DOI: 10.1016/j.anai.2016.12.009
Masuyama K, Goto M, Takeno S, Ohta N, Okano M, Kamijo A, et al. Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients. Auris Nasus Larynx. 2016;43(1):1-9. DOI: 10.1016/j.anl.2015.08.015
Ohashi-Doi K, Kito H, Du W, Nakazawa H, Ipsen H, Gudmann P, et al. Bioavailability of house dust mite allergens in sublingual allergy tablets is highly dependent on the formulation. Int Arch Allergy Immunol. 2017;174(1):26-34. DOI: 10.1159/000479693
Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA. 2017;317(6):615-625. DOI: 10.1001/jama.2016.21040
Larenas-Linnemann D, Esch R, Plunkett G, Brown S, Maddox D, Barnes C, et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann Allergy Asthma Immunol. 2011;107(5):448-458. DOI: 10.1016/j.anai.2011.07.001
Sander I, Fleischer C, Meurer U, Bruning T, Raulf-Heimsoth M. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy. 2009;64(10):1486-1492. DOI: 10.1111/j.1398-9995.2009.02040.x
Larenas-Linnemann DE, Mösges R. Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Allergy Asthma Proc. 2016;37(1):50-56. DOI: 10.2500/aap.2016.37.3907
Larenas-Linnemann D, Cruz AA, Gutiérrez IR, Rodriguez P, Shah-Hosseini K, Michels A, et al. European and Mexican vs US diagnostic extracts of Bermuda grass and cat in skin testing. Ann Allergy Asthma Immunol. 2011;106(5):421-428. DOI: 10.1016/j.anai.2010.11.020
Nolte H, Plunkett G, Grosch K, Larsen JN, Lund K, Bollen M. Major allergen content consistency of SQ house dust mite sublingual immunotherapy tablets and relevance across geographic regions. Ann Allergy Asthma Immunol. 2016;117(3):298-303. DOI: 10.1016/j.anai.2016.07.004
Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802-809. DOI: 10.1016/j.jaci.2005.12.1358
Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-1345. DOI: 10.1016/j.jaci.2007.07.046
Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006;61(10):1177-1783. DOI: 10.1111/j.1398-9995.2006.01190.x
Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125(3):660-666. DOI: 10.1016/j.jaci.2009.12.931
Creticos PS, Esch RE, Couroux P, Gentile D, D’Angelo P, Whitlow B, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133(3):751-758. DOI: 10.1016/j.jaci.2013.10.041
Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131(5):1342-1349. DOI: 10.1016/j.jaci.2013.03.019
Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol. 2008;100(5):475-481. DOI: 10.1016/S1081-1206(10)60474-7
Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608-1614. DOI: 10.1016/j.jaci.2013.11.012
Demoly P, Okamoto Y, Yang WH, Devillier P, Bergmann KC. 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. Expert Rev Clin Immunol. 2016;12(11):1141-1151. DOI: 10.1080/1744666X.2016.1237288
Mosbech H, Canonica GW, Backer V, De-Blay F, Klimek L, Broge L, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015;114(2):134-140. DOI: 10.1016/j.anai.2014.11.015
Matsuoka T, Bernstein DI, Masuyama K, Nolte H, Okamiya K, Seitzberg D, et al. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. Pediatr Allergy Immunol. 2017;28(7):661-667. DOI: 10.1111/pai.12747
Henmar H, Frisenette SM, Grosch K, Nielsen K, Smith G, Sonderkaer S, et al. Fractionation of source materials leads to a high reproducibility of the SQ house dust mite SLIT-tablets. Int Arch Allergy Immunol. 2016;169(1):23-32. DOI: 10.1159/000444016
Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993;91(3):709-722. DOI: 10.1016/0091-6749(93)90190-Q
Larenas-Linnemann D. Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016;116(4):274-286. DOI: 10.1016/j.anai.2016.02.008
Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2017;72(3):435-443. DOI: 10.1111/all.12996
Larenas-Linnemann D, Matta JJ, Shah-Hosseini K, Michels A, Mösges R. Skin prick test evaluation of Dermatophagoides pteronyssinus diagnostic extracts from Europe, Mexico, and the United States. Ann Allergy Asthma Immunol. 2010;104(5):420-425. DOI: 10.1016/j.anai.2010.03.009
Moreno-Ancillo A, Moreno C, Ojeda P, Domínguez C, Barasona MJ, García-Cubillana A, et al. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing. J Investig Allergol Clin Immunol. 2007;17(6):399-405.
Marogna M, Spadolini I, Massolo A, Zanon P, Berra D, Chiodini E, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol. 2007;98(3):274-280. DOI: 10.1016/S1081-1206(10)60718-1
Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol. 2012;130(1):215-224. DOI: 10.1016/j.jaci.2012.04.021
Smits HH, Engering A, van Der Kleij D, De Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115(6):1260-1267. DOI: 10.1016/j.jaci.2005.03.036
Tankersley MS, Ledford DK. Stinging insect allergy: state of the art 2015. J Allergy Clin Immunol Pract. 2015;3(3):315-322. DOI: 10.1016/j.jaip.2015.03.012
Patel S, Ledford D. Killer Insects: Who is at risk for anaphylaxis? Curr Treat Options Allergy. 2016;3(3):235-242. DOI: 10.1007/s40521-016-0086-0
Calabria CW, Hauswirth DW, Rank M, Sher L, Larenas-Linnemann D. American Academy of Asthma, Allergy & Immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children. Allergy Asthma Proc. 2017;38(2):121-129. DOI: 10.2500/aap.2017.38.4024
Pérez-Vanzzini R, González-Díaz SN, Arias-Cruz A, Palma-Gómez S, Yong-Rodríguez A, Gutierrez-Mujica JJ, et al. Hipersensibilidad a la picadura de mosquito manifestada como síndrome de Skeeter. Rev Alerg Mex. 2015;62(1):83-87. DOI: 10.29262/ram.v62i1.62
Peng Z, Xu WW, Sham Y, Lam H, Sun D, Cheng L, et al. Mosquito salivary allergen Aed a 3: cloning, comprehensive molecular analysis, and clinical evaluation. Allergy. 2016;71(5):621-628. DOI: 10.1111/all.12812
Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597-1631. DOI: 10.1111/all.13201
Celi G, Brusca I, Scala E, Villalta D, Pastorello E, Farioli L, et al. House dust mite allergy in Italy-Diagnostic and clinical relevance of Der p 23 (and of minor allergens): a real-life, multicenter study. Allergy. 2019. DOI: 10.1111/all.13776
Turkeltaub PC, Campbell G, Mosimann JE. Comparative safety and efficacy of short ragweed extracts differing in potency and composition in the treatment of fall hay fever. Use of allergenically bioequivalent doses by parallel line bioassay to evaluate comparative safety and efficacy. Allergy. 1990;45(7):528-546. DOI: 10.1111/j.1398-9995.1990.tb00529.x
Villa E, Garelli V, Braido F, Melioli G, Canonica G. May we strengthen the human natural defenses with bacterial lysates? World Allergy Organ J. 2010;3(Suppl 8):S17-S23. DOI: 10.1097/WOX.0b013e3181ee0cfd
Alecsandru D, Valor L, Sánchez-Ramón S, Gil J, Carbone J, Navarro J, et al. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol. 2011;164(1):100-107. DOI: 10.1111/j.1365-2249.2011.04320.x
Wohrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol. 2007;144(2):137-142. DOI: 10.1159/000103225
Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996;97(6):1207-1213. DOI: 10.1016/S0091-6749(96)70186-0
Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol. 2001;107(1):81-86. DOI: 10.1067/mai.2001.111852
Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026-1045. DOI: 10.1111/all.12437
Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466-469. DOI: 10.1016/S0140-6736(77)91953-5
Eller E, Muraro A, Dahl R, Mortz CG, Bindslev-Jensen C. Assessing severity of anaphylaxis: a data-driven comparison of 23 instruments. Clin Transl Allergy. 2018;8:29. DOI: 10.1186/s13601-018-0215-x
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125(3):569-574. DOI: 10.1016/j.jaci.2009.10.060
Simons FE, Ebisawa M, Sánchez-Borges M, Thong BY, Worm M, Tanno LK, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):32. DOI: 10.1186/s40413-015-0080-1
Roy SR, Sigmon JR, Olivier J, Moffitt JE, Brown DA, Marshall GD. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2007;99(1):82-86. DOI: 10.1016/S1081-1206(10)60626-6
Bernardini R, Novembre E, Ingargiola A, Veltroni M, Mugnaini L, Cianferoni A, et al. Prevalence and risk factors of latex sensitization in an unselected pediatric population. J Allergy Clin Immunol. 1998;101(5):621-625. DOI: 10.1016/S0091-6749(98)70169-1
Garabrant DH, Schweitzer S. Epidemiology of latex sensitization and allergies in health care workers. J Allergy Clin Immunol. 2002;110(Suppl 2):S82-95.
Nettis E, Colanardi MC, Soccio AL, Marcandrea M, Pinto L, Ferrannini A, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol. 2007;156(4):674-681. DOI: 10.1111/j.1365-2133.2006.07738.x
Cisteró-Bahima A, Sastre J, Enrique E, Fernández M, Alonso R, Quirce S, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol. 2004;14(1):17-25. Disponible en: http://www.jiaci.org/issues/vol14issue01/17-25.pdf
Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy. 2006;61(10):1236-1237. DOI: 10.1111/j.1398-9995.2006.01155.x
Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2013;131(4):1084-1091. DOI: 10.1016/j.jaci.2012.12.662
Bachert C, Noergaard-Andreasen J. Cost-effectiveness of immunotherapy in the treatment of seasonal allergic rhinitis: identifying product-specific parameters of relevance for health care decision-makers and clinicians. Int Arch Allergy Immunol. 2015;168(3):213-217. DOI: 10.1159/000443272
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2019 Revista Alergia México